Clover Health Investments, Corp. operates as a medicare advantage insurer in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. Clover Health Investments, Corp. was incorporated in 2014 and is based in Franklin, Tennessee.

Clover Health Investments, Corp.

WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health, positioning Clover as a national leader in AI-enabled healthcare transformation.

Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way

Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.

Here's Why You Should Add CLOV Stock to Your Portfolio Now

Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now

While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains industry-leading medical cost ratios despite the short-term cost headwinds, a testament to its tech-based business model. The implementation of negotiated drug prices in 2026, combined with the 5.06% MA payout increase by CMS and the 5% quality bonus, could help Clover offset the higher medical costs.

Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential

Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.

CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financial Officer Ryan Schmidt - Corporate Participant Investor Relations Analyst - Corporate Participant Conference Call Participants John Granville Pinney - Canaccord Genuity Corp., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Ladies and gentlemen, good afternoon, and welcome to the Clover Health Second Quarter 2025 Earnings Conference Call.

Clover Health Investments, Corp. (CLOV) Q2 2025 Earnings Call Transcript

Clover Health Investments, Corp. (CLOV) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.01 per share a year ago.

Clover Health Investments, Corp. (CLOV) Q2 Earnings Meet Estimates

Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-year Second quarter 2025 Total revenues of $478 million, up 34% year-over-year Second quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpoint Maintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpoint Improves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage of Total revenues between 18% - 19% Maintains Adjusted EBITDA profitability between $50 million and $70 million Maintains Adjusted Net income between $50 million and $70 million Expects Insurance BER now between 88.5% - 89.5% WILMINGTON, Del., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today reported financial results for the second quarter 2025.

Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

New whitepaper shows that a relationship with a primary care physician (“PCP”) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (“COPD”) diagnosis, increased specialty care, and meaningful reductions in hospitalizations (15% lower) and 30-day readmissions (18% lower).

Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease

CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.

Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?

WILMINGTON, Del., July 31, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyone on Medicare, strongly supports the White House and Centers for Medicare & Medicaid Services' (CMS) announcement calling on the healthcare industry to “tear down digital walls” and build a truly patient-centric, interoperable ecosystem.

Clover Health Applauds White House and CMS' Push to “Tear Down Digital Walls,” Accelerating and Simplifying Access to Health Data for Patients and Their Clinicians

WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician-enablement platform, today announced the appointment of Vicky Bruner as Vice President of Operations.

Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution

In this piece, we'll check in on two mid-cap health insurance plays that are leveraging their tech-savvy and digital strengths to grab a bigger slice of the health insurance industry.

OSCR vs. CLOV: Which Stock Is A Better Buy Now?

PARIS--(BUSINESS WIRE)--TotalEnergies (Paris:TTE) (LSE:TTE) (NYSE:TTE) announces the start of production from the BEGONIA and CLOV Phase 3 offshore projects, leveraging ullage in the PAZFLOR and CLOV floating production, storage and offloading units (FPSO) to add a total of 60,000 barrels a day of new production. These two subsea tie-back projects deliver additional production leveraging available capacity on existing FPSO's and as such have low marginal costs and low carbon intensities. BEGONI.

TotalEnergies - Angola: Start-up of BEGONIA and CLOV Phase 3 Offshore Projects

WILMINGTON, Del., July 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that its Chief Financial Officer, Peter Kuipers, will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 11:00 a.m. Eastern Time.

Clover Health to Participate in Upcoming Canaccord Genuity 45th Annual Growth Conference

WILMINGTON, Del., July 17, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a physician enablement company bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph (Joe) Oldakowski as Vice President of Finance and Controller. In this role, Mr. Oldakowski reports to Chief Financial Officer Peter Kuipers and will lead Clover's corporate accounting, GAAP, SEC, and statutory financial reporting and tax function.

Clover Health Appoints Joseph Oldakowski as Vice President of Finance and Controller

WILMINGTON, Del., July 09, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover Health”), a leading Medicare Advantage company committed to affordable, high-quality care, today announced the launch of a new community-based pharmacy pilot program across New Jersey.

Clover Health Launches New Jersey Community Pharmacy Program in Partnership with IPC's iCare+ Network

WILMINGTON, Del., July 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Tuesday, August 5, 2025. Company management will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the company's business and financial performance for the quarter.

Clover Health to Report Second Quarter 2025 Financial Results on August 5, 2025

Real-time stock quote and overview for CLOV